Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
Most Cited Paper
in Retinal Diseases and Treatments
18 Months Post-Publication
Class of 2026
“Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026/
Topics
RGX-314 · Neovascular age-related macular degeneration · Subretinal injection · Gene therapy · dose-escalation study · Adeno-associated virus (AAV) vector · Anti-VEGF therapy · phase 1/2a clinical trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459